乳杆菌paracasei WIS43通过调节肠道微生物群和抑制炎症来缓解DSS诱导的大肠炎
Yu Fu1, Shuxia Chen1, Lei Cui2
1School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Frontiers in microbiology
|February 16, 2026
概括
新型益生菌Lactobacillus paracasei WIS43通过减少炎症和恢复肠道微生物群平衡,有效治疗小鼠的性结肠炎 (UC). 这种菌株对UC患者来说是一个有希望的治疗选择.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,发病率越来越高,治疗选择有限.
- 益生菌正在为UC探索,但菌株特异性影响需要进一步定义.
- 乳酸菌种在UC患者中经常被耗尽,这表明这些细菌的作用.
研究的目的:
- 在性结肠炎的小鼠模型中研究Lactobacillus paracasei WIS43的治疗潜力.
- 为了比较WIS43对梅萨拉和另一种商用Lactobacillus paracasei菌株 (LPC-37) 的疗效.
- 阐明WIS43对宿主免疫和肠道微生物群的影响背后的机制.
主要方法:
- 进行了微生物组数据集的元分析,以评估UC中的Lactobacillus丰度.
- 使用硫酸 (DSS) 诱导的小鼠结肠炎模型来评估WIS43.
- 分析了疾病活动,组织病理学,细胞因子水平和肠道微生物群组成 (16S rRNA测序).
主要成果:
- 分析证实了UC患者的乳酸菌枯竭.
- WIS43治疗显著改善了结肠炎症状,包括体重减轻和结肠缩短.
- 通过减少关键细胞因子 (TNF-α,IL-6,IL-1β) 和恢复有益的肠道细菌,WIS43显示出强大的抗炎作用.
结论:
- 乳酸菌 WIS43是治疗性结肠炎的有希望的益生菌候选者.
- WIS43通过调节宿主免疫力和重新平衡肠道微生物群来发挥治疗作用.
- 需要进一步的临床研究来证实WIS43在人类UC患者中的疗效.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
754
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
754
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
915
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
915
Drugs for Treatment of Constipation-Predominant IBS
899
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
899
Irritable Bowel Syndrome III: Medical and Nursing Management
917
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
917
Drugs for Treatment of Ulcerative Colitis in IBD
544
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
544


